Study guide
3.5 Reanalysis, Reclassification & Validity/Utility Framework
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
3.5 Reanalysis, Reclassification & Validity/Utility Framework
Key Takeaways Explain This Topic AI
Variant reclassification occurs when new evidence (population data, functional studies, segregation, gene-disease validity updates, or specialty guidelines) shifts a call among P/LP/VUS/LB/B tiers
Periodic reanalysis of unsolved exome/genome data can yield new diagnoses as bioinformatics pipelines, gene–disease associations, and phenotype annotations improve
Analytic validity addresses whether the assay correctly detects the genotype it claims to measure (analytical sensitivity/specificity, quality metrics)
Clinical validity addresses how well a genotype predicts or explains the phenotype (penetrance, spectrum, gene–disease relationship strength)
Clinical utility addresses whether testing improves decisions, outcomes, or patient-important endpoints—analytic and clinical validity are necessary but not sufficient for utility
Last updated: August 2026
3.5 Reanalysis, Reclassification & Validity/Utility Framework
Quick Answer: Reclassification updates a variant’s ACMG/AMP tier when evidence changes; reanalysis revisits unsolved WES/WGS (and sometimes panel) data as genes, pipelines, and phenotypes evolve. Separate analytic validity (assay correctly detects the genotype), clinical validity (genotype–phenotype relationship is real and characterized), and clinical utility (results improve decisions/outcomes).
Domain 3A pairs interpretation skill with systems thinking: a beautiful classification is useless if the assay missed the variant, if the gene–disease link is weak, or if knowing the result cannot change care. Boards test these distinctions with short vignettes.
Reclassification: Why Calls Change
A classification is a snapshot of evidence at a point in time. Common triggers that move a variant across tiers:
- Trigger Example effect on classification
- Updated population databases Former “rare” missense appears too common → shift VUS/LP toward LB/B
- New functional assays Demonstrated protein defect → VUS toward LP/P; no effect → toward LB
Family segregation Variant fails to track with disease in multiple meiosis → benign-leaning; tracks tightly in a highly penetrant phenotype → pathogenic-leaning
Gene-specific ACMG/ClinGen rules Strength of PVS1 or PP3 adjusted; same variant data, new weight
Gene–disease validity revision Gene removed from strong association panels → prior “explanatory” variant reconsidered
Phenotype reassessment Clinical diagnosis revised; variant in a mismatched gene loses clinical weight
Counseling implications when P/LP → VUS or LB/B: Patients and relatives may have made cascade testing or management decisions based on the old call. Ethically and practically, explain what changed , which relatives need updated counseling , and which medical recommendations should be revised (e.g., stop treating a downgraded variant as a predictive marker). Document recontact attempts per clinic policy.
Counseling implications when VUS → LP/P: This can convert an unsolved or partially explained case into an actionable molecular diagnosis. Offer appropriate cascade testing, refine recurrence risk, and align surveillance with gene-specific guidelines. Check whether prior “negative” relative testing needs reinterpretation if only the proband’s VUS was discussed casually.
Who initiates updates? Labs may issue amended reports; clinics may subscribe to reclassification alerts; patients may return years later. Know your recontact policy limitations—promise only what your system can deliver.
Periodic Reanalysis of WES/WGS
A non-diagnostic exome or genome is not always a permanent dead end. Reanalysis means bioinformaticians/clinicians re-interpret stored sequencing data (sometimes with updated phenotype HPO terms), not necessarily redrawing blood.
Why yield improves over time:
New gene–disease discoveries add genes that were not curated at the original analysis.
Improved variant calling and annotation recover indels, CNVs, mitochondrial variants, or splicing effects previously missed.
Richer phenotype from longitudinal follow-up narrows candidate lists.
Updated classification frameworks re-rank the same variants.
Segregation or additional family sequencing becomes available.
Practical counseling points: Quote that a fraction of initially negative exomes later become positive on reanalysis (published cohorts vary by indication and interval—teach the concept , not a single magic percentage). Discuss timing (often after 12–24 months or when phenotype evolves—practice varies), cost/coverage , and that reanalysis differs from ordering an entirely new test technology (though sometimes a newer platform is warranted).
Scenario: A child with epilepsy and developmental delay had a non-diagnostic trio exome in 2018. In 2026, reanalysis flags a de novo variant in a gene curated after 2020 with strong LoF mechanism evidence → new LP/P diagnosis. Counseling shifts from empiric recurrence discussion to variant-specific reproductive options and syndrome-specific management.
Analytic Validity vs Clinical Validity vs Clinical Utility
These three terms appear across genetic testing policy, NSGC/ABGC-style ethics/practice items, and test-selection questions.
Concept Core question Genetic counseling examples
Analytic validity Does the test accurately and reliably detect the genotype (or analyte) it claims to measure? Does this NGS panel reliably call exons of interest? Are deletion/duplications covered or do you need MLPA? Is hemoglobin electrophoresis analytically adequate for the indicated thalassemia workup?
Clinical validity How well does the genotype (or marker) relate to the presence, risk, or severity of disease? Penetrance of a BRCA1 pathogenic variant for breast cancer; positive/negative predictive value of a carrier screen in a population; strength of gene–disease association for a candidate gene
Clinical utility Does testing improve health outcomes, clinical decision-making, or patient-important endpoints (including sometimes psychosocial/reproductive planning, depending on framework)? Will identifying Lynch syndrome change colonoscopy interval? Will a VUS-heavy panel without management pathway help this patient—or mainly create anxiety?
Analytic validity — worked examples
Fragile X: Ordering an NGS panel that poorly covers FMR1 repeat expansion has poor analytic validity for fragile X syndrome even if the lab is CAP/CLIA certified for sequencing generally. Choose an expansion-appropriate assay.
NGS depth/coverage: A report claiming “negative panel” despite low coverage of a critical exon has analytic limitations; counselors ask about coverage gaps , supplemental Sanger , and CNV methods .
Clinical validity — worked examples
A pathogenic variant in a well-established gene with quantified penetrance has strong clinical validity for risk counseling.
A rare variant in a gene with only limited case reports has uncertain clinical validity even if analytic detection was perfect—this overlaps VUS/gene-validity problems.
Polygenic risk scores may have population-dependent clinical validity; applying a score derived in one ancestry group unchanged to another can weaken validity.
Clinical utility — worked examples
Diagnosing OTC deficiency in a neonate can have clear utility (dietary/medication management, family testing, reproductive risk).
Broad panel testing in a patient whose differential is already solved clinically—and where results will not alter therapy—may have limited utility despite perfect analytic performance.
Predictive testing for a neurodegenerative disorder without prevention may still hold personal utility for life planning for some patients; exam items often distinguish medical utility from personal/psychosocial motivations—clarify which definition a stem uses.
Integration rule for test selection: High analytic validity is required first; clinical validity determines what you can claim about disease; clinical utility determines whether offering the test is appropriate now for this patient’s goals and available actions.
Putting It Together in a Session
Before ordering: match technology to the variant types you must detect (analytic validity).
Before interpreting: demand gene–disease and variant evidence (clinical validity / ACMG tier).
Before recommending action: ask what decision changes (clinical utility).
After a negative or VUS exome: schedule or explain reanalysis/reclassification pathways rather than closing the book forever.
After an amended report: update the pedigree’s molecular annotations and re-counsel relatives whose plans hinged on the prior call.
Variant interpretation is a longitudinal process. The CGC exam rewards counselors who treat reports as living documents inside a validity/utility framework—not one-time labels carved in stone.